Giuliano De Carolis 1 , Mery Paroli 1 , Lara Tollapi 1 , Matthew W Doust 2 , Abram H Burgher 3 , Cong Yu 4 , Thomas Yang 4 , Donna M Morgan 5 , Kasra Amirdelfan 6 , Leonardo Kapural 7 , B Todd Sitzman 8 , Richard Bundschu 9 , Ricardo Vallejo 10 , Ramsin M Benyamin 10 , Thomas L Yearwood 11 , Bradford E Gliner 12 , Ashley A Powell 13 , Kerry Bradley 13
Spinal cord stimulation (SCS) has been successfully used to treat chronic intractable pain for over 40 years. Successful clinical application of SCS is presumed to be generally dependent on maximizing paresthesia-pain overlap; critical to achieving this is positioning of the stimulation field at the physiologic midline. Recently, the necessity of paresthesia for achieving effective relief in SCS has been challenged by the introduction of 10 kHz paresthesia-free stimulation. In a large, prospective, randomized controlled pivotal trial, HF10 therapy was demonstrated to be statistically and clinically superior to paresthesia-based SCS in the treatment of severe chronic low back and leg pain. HF10 therapy, unlike traditional paresthesia-based SCS, requires no paresthesia to be experienced by the patient, nor does it require paresthesia mapping at any point during lead implant or post-operative programming.